Efficacy of compound xueshuantong capsule in reducing cardiovascular diseases and associated ophthalmic complications: a multi-centre retrospective study

This study aims to explore the effectiveness and value of compound xueshuantong capsule (CXC) in the treatment of diseases by evaluating its potential to reduce cardiovascular diseases (CVDs) and ophthalmic complications. A total of 5 104 patients with fundus vascular diseases including retinal artery occlusion (RAO), retinal vein occlusion (RVO), diabetic retinopathy (DR), hypertensive retinopathy, periphlebitis of retina, age-related macular degeneration (AMD), central serous chorioretinopathy (CSC), and anterior ischaemic optic neuropathy (AION) were enroled across seven hospitals from 2002 to 2022. All participants were randomised categorised into two groups: CXC combination group (CXC alone or combined with hypoglycemic, lipid-lowering, or anti-hypertensive drugs, and other microcirculation and fundus angiopathy medications), and non-CXC group (only taking the above-mentioned medicines). Kaplan-Meier curves illustrated a lower incidence of cardio-cerebrovascular events and ophthalmic complications in CXC group compared with other group at a significant difference observed. Further stratification revealed a decreased risk of ophthalmic complications in CXC group, and supported by multivariate analysis through adjusting for baseline confounding factors. Our findings further confirmed the potential value of CXC in treating cardio-cerebrovascular diseases and associated ophthalmic complications, and accompanying with less side effects at the same time.